All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
GvHD Hub Co-Chair Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne Université, Paris, FR, provides an overview of the practice-changing abstracts from this year's virtual American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Annual Congress.
Practice-changing abstracts at ASCO and EHA 2020
Mohamad Mohty highlights 2020 as a major year for GvHD. In particular, 2020 saw the publication of the first positive phase III trial for steroid-refractory GvHD.
Subgroup analysis of ruxolitinib in patients with steroid-refractory acute GvHD – update from EHA 2020
A follow-up analysis of the REACH2 study, which examined responses in different subgroups of patients of the trial
Two different treatment approaches in combination with ECP for the management of steroid refractory aGvHD: etanercept and ruxolitinib
Two different studies have recently reported results using extracorporeal photopheresis in combination with other...
Subscribe to get the best content related to GvHD delivered to your inbox